ADMA Biologics Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA Biologics stock.
View analyst ratings for ADMA Biologics or view top-rated stocks.

Wall Street analysts have given ADMA Biologics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ADMA Biologics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for ADMA Biologics.

ADMA Biologics, Inc. (NASDAQ:ADMA) announced its quarterly earnings data on Tuesday, November, 10th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). The biotechnology company had revenue of $10.28 million for the quarter, compared to analysts' expectations of $9.55 million. ADMA Biologics had a negative net margin of 166.01% and a negative trailing twelve-month return on equity of 98.83%.
View ADMA Biologics' earnings history.

ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADMA shares have decreased by 9.5% and is now trading at $2.09.
View which stocks have been most impacted by COVID-19.

ADMA Biologics issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 19th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $13.9-13.9 million, compared to the consensus revenue estimate of $12.05 million.

4 brokerages have issued 1-year target prices for ADMA Biologics' shares. Their forecasts range from $6.00 to $11.00. On average, they expect ADMA Biologics' stock price to reach $8.00 in the next year. This suggests a possible upside of 282.8% from the stock's current price.
View analysts' price targets for ADMA Biologics or view top-rated stocks among Wall Street analysts.

9 employees have rated ADMA Biologics CEO Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among ADMA Biologics' employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ADMA Biologics include CEL-SCI (CVM), Cellectis (CLLS), Vaxart (VXRT), Orchard Therapeutics (ORTX), Osiris Therapeutics (OSIR), Tarsus Pharmaceuticals (TARS), Athira Pharma (ATHA), Agenus (AGEN), Precision BioSciences (DTIL), DBV Technologies (DBVT), Jounce Therapeutics (JNCE), Solid Biosciences (SLDB), Compugen (CGEN), MeiraGTx (MGTX) and Curis (CRIS).
View all of ADMA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), Cannabics Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

ADMA Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.74%), Northern Trust Corp (0.90%), Essex Investment Management Co. LLC (0.66%), Magnetar Financial LLC (0.59%), Alyeska Investment Group L.P. (0.49%) and Alyeska Investment Group L.P. (0.49%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive and Perceptive Advisors Llc.
View institutional ownership trends for ADMA Biologics.

ADMA stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Alyeska Investment Group L.P., BlackRock Inc., Avantax Advisory Services Inc., Alliancebernstein L.P., Dynamic Technology Lab Private Ltd, Hussman Strategic Advisors Inc., and ProShare Advisors LLC.
View insider buying and selling activity for ADMA Biologics or view top insider-selling stocks.

ADMA stock was purchased by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Principal Financial Group Inc., Essex Investment Management Co. LLC, Squarepoint Ops LLC, ExodusPoint Capital Management LP, GSA Capital Partners LLP, New York Life Investments Alternatives, and Meridian Wealth Management LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for ADMA Biologics or or view top insider-buying stocks.

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADMA stock can currently be purchased for approximately $2.09.

ADMA Biologics has a market capitalization of $197.61 million and generates $29.35 million in revenue each year. The biotechnology company earns $-48,280,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

ADMA Biologics employs 313 workers across the globe.

The official website for ADMA Biologics is www.admabiologics.com.

ADMA Biologics is headquartered at 465 STATE ROUTE 17, RAMSEY NJ, 07446.

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]